DURHAM, N.C. -- The Bill & Melinda Gates Foundation has awarded a new grant to Duke University Medical Center for work developing vaccines that can induce IgA antibodies for preventing HIV-1 infection. This award comes from the Gates' Collaboration for AIDS Vaccine Discovery (CAVD) program.
Late in 2011, Duke also won three grants from CAVD that totaled $37.2 million.
The latest grant award is a 3-year, $8.9 million grant to Barton Haynes, M.D., a national leader in AIDS/HIV research and director of the Center for HIV/AIDS Vaccine Immunology (CHAVI), as well as director of the Duke Human Vaccine Institute (DHVI).
The award stems from promising discoveries from the analysis of the how a partially effective HIV-1 vaccine might have worked, that was carried out under Dr. Haynes' leadership. Haynes led a multinational group that analyzed a wealth of data from the RV144 trial in Thailand, which tested a combination vaccine for efficacy.
"We are grateful to the Gates Foundation and its Collaboration for AIDS Vaccine Discovery for their continued support that lets us explore important new findings," said Haynes, who is Frederic M. Hanes Professor of Medicine and Immunology at Duke. "We believe the latest analyses are yielding critical information, and we are poised to move into promising new phases of studies for vaccine development in the fight against AIDS."
This CAVD award will fund research into ways to induce protective IgA human antibodies by vaccines to prevent HIV-1 infection, as well as to learn how to not induce IgA antibodies that might block the protective effect of other antibodies. In learning how to induce the right IgAs, recombinant IgAs will be produced to be tested as therapies to prevent HIV.
The new award will support work to elaborate on studies recently completed by Haynes and his Duke colleague Georgia Tomaras, Ph.D., who found that IgA was induced in plasma in the RV144 HIV prevention
|Contact: Mary Jane Gore|
Duke University Medical Center